1. Home
  2. TIL vs RFAI Comparison

TIL vs RFAI Comparison

Compare TIL & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • RFAI
  • Stock Information
  • Founded
  • TIL 2018
  • RFAI 2024
  • Country
  • TIL United States
  • RFAI Singapore
  • Employees
  • TIL N/A
  • RFAI N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • RFAI
  • Sector
  • TIL Health Care
  • RFAI
  • Exchange
  • TIL Nasdaq
  • RFAI NYSE
  • Market Cap
  • TIL 134.5M
  • RFAI 153.0M
  • IPO Year
  • TIL 2021
  • RFAI 2024
  • Fundamental
  • Price
  • TIL $20.97
  • RFAI $10.25
  • Analyst Decision
  • TIL Strong Buy
  • RFAI
  • Analyst Count
  • TIL 4
  • RFAI 0
  • Target Price
  • TIL $114.00
  • RFAI N/A
  • AVG Volume (30 Days)
  • TIL 103.6K
  • RFAI 19.6K
  • Earning Date
  • TIL 11-13-2024
  • RFAI 01-01-0001
  • Dividend Yield
  • TIL N/A
  • RFAI N/A
  • EPS Growth
  • TIL N/A
  • RFAI N/A
  • EPS
  • TIL N/A
  • RFAI N/A
  • Revenue
  • TIL N/A
  • RFAI N/A
  • Revenue This Year
  • TIL N/A
  • RFAI N/A
  • Revenue Next Year
  • TIL $2.65
  • RFAI N/A
  • P/E Ratio
  • TIL N/A
  • RFAI N/A
  • Revenue Growth
  • TIL N/A
  • RFAI N/A
  • 52 Week Low
  • TIL $9.20
  • RFAI $10.25
  • 52 Week High
  • TIL $92.00
  • RFAI $10.27
  • Technical
  • Relative Strength Index (RSI)
  • TIL 46.36
  • RFAI N/A
  • Support Level
  • TIL $18.56
  • RFAI N/A
  • Resistance Level
  • TIL $22.00
  • RFAI N/A
  • Average True Range (ATR)
  • TIL 1.98
  • RFAI 0.00
  • MACD
  • TIL 0.36
  • RFAI 0.00
  • Stochastic Oscillator
  • TIL 28.05
  • RFAI 0.00

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About RFAI RF ACQUISITION CORP II

RF Acquisition Corp II is a blank check company.

Share on Social Networks: